A mutiple dose, randomized, double-blind, placebo-controlled study of subcutaneous AMG 108 in patients with type 2 diabetes mellitus.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 05 Feb 2009
At a glance
- Drugs MEDI 8968 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Amgen
- 07 Jun 2017 Biomarkers information updated
- 05 Feb 2009 Actual initiation date (Jun 2008) added as reported by ClinicalTrials.gov.
- 05 Feb 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.